This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

The Changing Landscape of Interstitial Lung Disease

The Changing Landscape of Interstitial Lung Disease



Time to Complete

1 hour


February 16, 2018


February 16, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Penn State College of Medicine

Commercial Supporter

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Program Description

Many patients with interstitial lung disease (ILD) do not receive a timely and accurate diagnosis prior to considerable disease progression. Management guidelines are vague and treatment options have been limited, leading to negative health outcomes and decreased quality of life. Advances in diagnostic strategies, recently approved therapies, and new clinical trial data, however, are changing best practices in the diagnosis and treatment of ILD. This activity will examine the signs and symptoms of ILD, strategies for timely diagnosis and accurate classification, and pharmacologic and nonpharmacologic treatment options.

Intended Audience

This activity is intended for pulmonologists, internal medicine specialists, primary care clinicians, radiologists, and other clinicians who encounter ILD.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Review the diagnosis and classification of ILD disorders
  • Discuss advances in ILD diagnosis and assessment
  • Outline treatment strategies for ILD
  • Recognize the importance of treating comorbidities

Conflict Of Interest Disclosure Policy

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.


Mary Beth Scholand, MD

Associate Professor of Pulmonary Medicine
Director of the Interstitial Lung Disease Clinic
University of Utah
Salt Lake City, UT

Dr. Scholand has disclosed the following:
Speakers Bureau: Roche/Genentech
Consultant: Boehringer Ingelheim, Roche/Genentech

Additional Content Development Faculty
Sonye K. Danoff, MD, PhD

Associate Professor of Medicine
Co-Director, Johns Hopkins ILD/IPF Program
Associate Director, Johns Hopkins Myositis Center
Baltimore, MD

Dr. Danoff has disclosed the following:
Grant/Research Support: Boehringer Ingelheim, Roche/Genentech
Consultant: Boehringer Ingelheim

Kevin R. Flaherty, MD, MS
Professor of Medicine
Director, University of Michigan Interstitial Lung Disease Program
Chair, Pulmonary Fibrosis Foundation
Clinical Care Network/Registry Steering Committee
Ann Arbor, MI

Dr. Flaherty has disclosed the following:
Grant/Research Support: Boehringer Ingelheim, Roche/Genentech
Consultant: Aeolus, Afferent, Boehringer Ingelheim, Fibrogen, Roche/Genentech, Sanofi-Genzyme, Veracyte

David J. Lederer, MD, MS
Associate Professor of Medicine
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center
New York, NY

Dr. Lederer has disclosed the following:
Consultant: FibroGen, Global Blood Therapeutics, Inc., Philips Respironics, Roche/Genentech, Sanofi Genzyme, Veracyte

Accredited Provider Disclosures

Penn State staff involved in the development and review of this activity have nothing to disclose.

Publishing Staff disclosures

The MCM Education planners and managers have nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.


The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; or Boehringer Ingelheim Pharmaceuticals, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.


To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or Please reference activity code G6190-18-T.


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue